AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 199 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $128,676,810 | -22.5% | 5,199,063 | -11.4% | 0.03% | -16.1% |
Q2 2023 | $166,114,585 | +26.4% | 5,865,628 | +2.5% | 0.03% | +19.2% |
Q1 2023 | $131,460,320 | -14.3% | 5,723,131 | +4.8% | 0.03% | -16.1% |
Q4 2022 | $153,391,408 | +5.4% | 5,462,657 | +6.1% | 0.03% | 0.0% |
Q3 2022 | $145,597,000 | +27.6% | 5,148,413 | 0.0% | 0.03% | +34.8% |
Q2 2022 | $114,140,000 | -23.8% | 5,148,413 | -0.0% | 0.02% | -11.5% |
Q1 2022 | $149,875,000 | -11.4% | 5,148,566 | 0.0% | 0.03% | -3.7% |
Q4 2021 | $169,233,000 | -29.2% | 5,148,566 | -0.7% | 0.03% | -34.1% |
Q3 2021 | $239,166,000 | -35.9% | 5,182,353 | -23.4% | 0.04% | -33.9% |
Q2 2021 | $373,079,000 | +5.4% | 6,769,715 | -1.2% | 0.06% | 0.0% |
Q1 2021 | $353,920,000 | +3.7% | 6,853,596 | -13.0% | 0.06% | -1.6% |
Q4 2020 | $341,327,000 | +23.3% | 7,877,370 | -0.4% | 0.06% | +10.5% |
Q3 2020 | $276,857,000 | -34.2% | 7,910,208 | +0.6% | 0.06% | -39.4% |
Q2 2020 | $420,720,000 | +50.5% | 7,866,877 | -0.2% | 0.09% | +27.0% |
Q1 2020 | $279,603,000 | -26.5% | 7,880,621 | -1.0% | 0.07% | -7.5% |
Q4 2019 | $380,172,000 | +74.8% | 7,961,723 | +18.6% | 0.08% | +63.3% |
Q3 2019 | $217,521,000 | -35.9% | 6,713,603 | -1.4% | 0.05% | -34.7% |
Q2 2019 | $339,495,000 | -38.2% | 6,806,240 | -16.5% | 0.08% | -39.5% |
Q1 2019 | $549,430,000 | +46.3% | 8,146,943 | +0.0% | 0.12% | +31.9% |
Q4 2018 | $375,479,000 | -38.1% | 8,143,116 | +3.5% | 0.09% | -26.6% |
Q3 2018 | $606,731,000 | -5.8% | 7,867,379 | +2.9% | 0.13% | -10.5% |
Q2 2018 | $644,081,000 | +1.3% | 7,646,700 | -1.6% | 0.14% | -0.7% |
Q1 2018 | $635,616,000 | +62.9% | 7,772,274 | +13.9% | 0.14% | +67.4% |
Q4 2017 | $390,220,000 | -13.6% | 6,825,600 | +0.8% | 0.09% | -17.3% |
Q3 2017 | $451,883,000 | +30.1% | 6,769,790 | +0.3% | 0.10% | +26.8% |
Q2 2017 | $347,211,000 | +0.9% | 6,748,487 | +14.5% | 0.08% | -1.2% |
Q1 2017 | $344,186,000 | +40.2% | 5,893,596 | +0.2% | 0.08% | +33.9% |
Q4 2016 | $245,459,000 | -19.9% | 5,882,068 | +1.4% | 0.06% | -19.5% |
Q3 2016 | $306,268,000 | +37.7% | 5,798,331 | +9.2% | 0.08% | +35.1% |
Q2 2016 | $222,423,000 | +3.4% | 5,309,050 | +0.2% | 0.06% | 0.0% |
Q1 2016 | $215,141,000 | -37.1% | 5,299,078 | +0.6% | 0.06% | -36.0% |
Q4 2015 | $341,965,000 | -2.7% | 5,267,467 | +5.8% | 0.09% | -9.2% |
Q3 2015 | $351,335,000 | -26.9% | 4,977,114 | +15.1% | 0.10% | -21.0% |
Q2 2015 | $480,670,000 | +57.0% | 4,324,916 | +33.3% | 0.12% | +57.0% |
Q1 2015 | $306,064,000 | +35.6% | 3,245,638 | +61.1% | 0.08% | +31.7% |
Q4 2014 | $225,702,000 | +121.2% | 2,014,480 | +21.1% | 0.06% | +114.3% |
Q3 2014 | $102,037,000 | +104.8% | 1,663,190 | +52.9% | 0.03% | +115.4% |
Q2 2014 | $49,826,000 | +14.7% | 1,087,432 | -2.0% | 0.01% | +8.3% |
Q1 2014 | $43,431,000 | +33.6% | 1,109,342 | -18.2% | 0.01% | +33.3% |
Q4 2013 | $32,497,000 | +6.0% | 1,356,893 | +23.8% | 0.01% | -10.0% |
Q3 2013 | $30,653,000 | – | 1,096,288 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |